PDF herunterladen
Thromb Haemost 2021; 121(07): 867-876
DOI: 10.1055/s-0040-1722192
Coagulation and Fibrinolysis

Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis

Emanuele Valeriani 
1   Department of Medical, Oral and Biotechnological Sciences, “G. d'Annunzio” University, Chieti, Italy
2   Diagnostic and Therapeutic Medicine Department, University Campus Bio-Medico of Rome, Rome, Italy
,
Marcello Di Nisio 
3   Department of Medicine and Ageing Sciences, “G. d'Annunzio” University, Chieti-Pescara, Italy
,
Nicoletta Riva 
4   Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
,
Omri Cohen
5   National Hemophilia Center, Institute of Thrombosis and Hemostasis and the Amalia Biron Research Institute, Sheba Medical Center, Tel-Hashomer, Israel
6   Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Ettore Porreca
1   Department of Medical, Oral and Biotechnological Sciences, “G. d'Annunzio” University, Chieti, Italy
,
Marco Senzolo
7   Multivisceral Transplant Unit, University Hospital of Padua, Padua, Italy
,
Andrea De Gottardi
8   Department of Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland
,
Marta Magaz
9   Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD. University of Barcelona, Barcelona, Spain
,
Juan-Carlos Garcia-Pagan
9   Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, IDIBAPS and CIBEREHD. University of Barcelona, Barcelona, Spain
,
Walter Ageno
10   Department of Medicine and Surgery, University of Insubria, Varese, Italy
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Splanchnic vein thrombosis (SVT) is a common complication in patients with liver cirrhosis. The aim of this study was to evaluate the efficacy and safety of anticoagulant therapy for SVT in cirrhotic patients.

Methods In this systematic review and meta-analysis, studies reporting on SVT recanalization and progression, recurrent venous thromboembolism (VTE), major bleeding, and overall mortality were searched in MEDLINE, EMBASE, and ClinicalTrial.gov up to December 2019. Pooled proportions and risk ratios (RRs) with corresponding 95% confidence intervals (CIs) were calculated.

Results A total of 1,475 patients were included in 26 studies (23 observational and 3 randomized controlled trials). In patients receiving anticoagulant therapy, SVT recanalization occurred in 68% (95% CI, 62–74; 571/842 patients; 22 studies), SVT progression in 6% (95% CI, 4–9; 25/748 patients; 22 studies), recurrent VTE in 10% (95% CI, 4–22; 48/399 patients; 7 studies), major bleeding in 6% (95% CI, 4–10; 58/785 patients; 18 studies), and overall mortality in 9% (95% CI, 6–14; 68/787 patients; 17 studies). Anticoagulant treatment was associated with higher SVT recanalization (RR 3.19; 95% CI, 1.42–7.17), lower thrombosis progression (RR 0.28; 95% CI, 0.15–0.52), major bleeding (RR 0.52; 95% CI, 0.28–0.97), and overall mortality (RR 0.42; 95% CI, 0.24–0.73) compared with no treatment.

Conclusion Anticoagulant therapy seems to improve vein recanalization and to reduce SVT progression, major bleeding, and overall mortality in cirrhotic patients with SVT. The incidence of recurrent VTE during anticoagulation remains substantial.

Keywords

anticoagulants - liver cirrhosis - portal vein - splanchnic circulation

Authors' Contributions

Study conception and design: E.V., M.D.N., N.R., W.A.; Data acquisition: E.V., O.C., M.D.N., N.R.; Statistical analysis: E.V., M.D.N., N.R.; Interpretation of the data: All authors; Drafting of the manuscript: E.V., M.D.N., N.R., W.A.; Critical revision of the manuscript for important intellectual content: All authors; Final approval of the manuscript: All authors.


Supplementary Material



Publikationsverlauf

Eingereicht: 22. Juni 2020

Angenommen: 17. November 2020

Artikel online veröffentlicht:
01. Februar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F. Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 2018; 118 (08) 1491-1506
    Thieme ConnectPubMedSuche in Google Scholar
  • 2 Nery F, Chevret S, Condat B. et al; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61 (02) 660-667
    Suche in Google Scholar
  • 3 Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology 2019; 156 (06) 1582-1599
    CrossrefPubMedSuche in Google Scholar
  • 4 Tripodi A, Primignani M, Chantarangkul V. et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137 (06) 2105-2111
    CrossrefPubMedSuche in Google Scholar
  • 5 La Mura V, Tripodi A, Tosetti G. et al. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. Liver Int 2016; 36 (09) 1322-1330
    CrossrefPubMedSuche in Google Scholar
  • 6 Zermatten MG, Fraga M, Moradpour D. et al. Haemostatic alterations in cirrhotic patients: from primary haemostasis to fibrinolysis. Hepatology 2020
    Suche in Google Scholar
  • 7 D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22 (01) 332-354
    CrossrefPubMedSuche in Google Scholar
  • 8 Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153 (02) 480-487
    CrossrefPubMedSuche in Google Scholar
  • 9 Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26 (01) 23-29
    CrossrefPubMedSuche in Google Scholar
  • 10 Pettinari I, Vukotic R, Stefanescu H. et al; BO-LIVES (BOlogna LIVEr vascular Studies). Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol 2019; 114 (02) 258-266
    CrossrefPubMedSuche in Google Scholar
  • 11 Luca A, Caruso S, Milazzo M. et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology 2012; 265 (01) 124-132
    CrossrefPubMedSuche in Google Scholar
  • 12 Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol 2013; 108 (04) 568-574
    CrossrefPubMedSuche in Google Scholar
  • 13 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol 2016; 64 (01) 179-202
    CrossrefPubMedSuche in Google Scholar
  • 14 Valeriani E, Riva N, Di Nisio M, Ageno W. Splanchnic vein thrombosis: current perspectives. Vasc Health Risk Manag 2019; 15: 449-461
    CrossrefPubMedSuche in Google Scholar
  • 15 Di Nisio M, Valeriani E, Riva N, Schulman S, Beyer-Westendorf J, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost 2020; 18 (07) 1562-1568
    CrossrefPubMedSuche in Google Scholar
  • 16 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
    CrossrefPubMedSuche in Google Scholar
  • 17 Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. Cochrane Handbook Syst Rev Intervent Version 2019. Accessed at https://training.cochrane.org/cochrane-handbook-systematic-reviews-interventions
  • 18 Sterne JA, Hernán MA, Reeves BC. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919
    Suche in Google Scholar
  • 19 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedSuche in Google Scholar
  • 20 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
    CrossrefPubMedSuche in Google Scholar
  • 21 Ageno W, Riva N, Schulman S. et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med 2015; 175 (09) 1474-1480
    CrossrefPubMedSuche in Google Scholar
  • 22 Ageno W, Dentali F, Squizzato A. How I treat splanchnic vein thrombosis. Blood 2014; 124 (25) 3685-3691
    CrossrefPubMedSuche in Google Scholar
  • 23 R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. Available at: https://www.R-project.org/2019
    Suche in Google Scholar
  • 24 Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis?. J Hepatol 2009; 51 (04) 632-634
    CrossrefPubMedSuche in Google Scholar
  • 25 Stine JG, Shah PM, Cornella SL. et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis. World J Hepatol 2015; 7 (27) 2774-2780
    CrossrefPubMedSuche in Google Scholar
  • 26 Yerdel MA, Gunson B, Mirza D. et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000; 69 (09) 1873-1881
    CrossrefPubMedSuche in Google Scholar
  • 27 Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014; 20 (10) 2555-2563
    CrossrefPubMedSuche in Google Scholar
  • 28 Senzolo M, Riva N, Dentali F. et al; IRSVT study investigators. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol 2018; 9 (08) 176
    CrossrefPubMedSuche in Google Scholar
  • 29 Senzolo M, , M Sartori T, Rossetto V. et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32 (06) 919-927
    CrossrefPubMedSuche in Google Scholar
  • 30 Cui SB, Shu RH, Yan SP. et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol 2015; 27 (08) 914-919
    CrossrefPubMedSuche in Google Scholar
  • 31 Wang Z, Jiang MS, Zhang HL. et al. Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial. Radiology 2016; 279 (03) 943-951
    CrossrefPubMedSuche in Google Scholar
  • 32 Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol 2019; 113: 86-91
    CrossrefPubMedSuche in Google Scholar
  • 33 Amitrano L, Guardascione MA, Scaglione M. et al. Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol 2012; 24 (12) 1381-1385
    CrossrefPubMedSuche in Google Scholar
  • 34 Artaza T, Lopes M, Romero M. et al. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis. Gastroenterol Hepatol 2018; 41 (10) 611-617
    CrossrefPubMedSuche in Google Scholar
  • 35 Cai M, Zhu K, Huang W. et al. Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up. J Vasc Interv Radiol 2013; 24 (12) 1808-1816
    CrossrefPubMedSuche in Google Scholar
  • 36 Cerini F, Gonzalez JM, Torres F. et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology 2015; 62 (02) 575-583
    Suche in Google Scholar
  • 37 Chen H, Liu L, Qi X. et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2016; 28 (01) 82-89
    CrossrefPubMedSuche in Google Scholar
  • 38 Chung JW, Kim GH, Lee JH. et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol 2014; 20 (04) 384-391
    CrossrefPubMedSuche in Google Scholar
  • 39 De Gottardi A, Trebicka J, Klinger C. et al; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017; 37 (05) 694-699
    CrossrefPubMedSuche in Google Scholar
  • 40 Delgado MG, Seijo S, Yepes I. et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10 (07) 776-783
    CrossrefPubMedSuche in Google Scholar
  • 41 Francoz C, Belghiti J, Vilgrain V. et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54 (05) 691-697
    CrossrefPubMedSuche in Google Scholar
  • 42 Hernández Conde M, Llop Herrera E, de la Revilla Negro J. et al. Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation. Rev Esp Enferm Dig 2016; 108 (11) 716-720
    PubMedSuche in Google Scholar
  • 43 Kwon J, Koh Y, Yu SJ, Yoon JH. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications. Thromb Res 2018; 163: 71-76
    CrossrefPubMedSuche in Google Scholar
  • 44 La Mura V, Braham S, Tosetti G. et al. Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2018; 16 (07) 1146-1152
    CrossrefPubMedSuche in Google Scholar
  • 45 Nagaoki Y, Aikata H, Daijyo K. et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res 2018; 48 (01) 51-58
    CrossrefPubMedSuche in Google Scholar
  • 46 Riva N, Ageno W, Poli D. et al; Italian Federation of Anticoagulation Clinics (FCSA), Italian Federation of Anticoagulation Clinics FCSA. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost 2015; 13 (06) 1019-1027
    CrossrefPubMedSuche in Google Scholar
  • 47 Rodriguez-Castro KI, Vitale A, Fadin M. et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31 (01) 34-42
    CrossrefPubMedSuche in Google Scholar
  • 48 Sanchez-Ocaña R, Tejedor-Tejada J, Cimavilla-Roman M. et al. Utility of oral anticoagulants as prophylaxis of recurrent portal thrombosis after liver transplantation. Transplant Proc 2019; 51 (01) 83-86
    CrossrefPubMedSuche in Google Scholar
  • 49 Werner KT, Sando S, Carey EJ. et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci 2013; 58 (06) 1776-1780
    CrossrefPubMedSuche in Google Scholar
  • 50 Wu S, Wu Z, Zhang X, Wang R, Bai J. The incidence and risk factors of portal vein system thrombosis after splenectomy and pericardial devascularization. Turk J Gastroenterol 2015; 26 (05) 423-428
    CrossrefPubMedSuche in Google Scholar
  • 51 Wan YM, Li YH, Wu HM. et al. Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: an observational study (STROBE compliant). Medicine (Baltimore) 2017; 96 (45) e8498
    CrossrefPubMedSuche in Google Scholar
  • 52 Yue-Meng W, Li YH, Wu HM, Yang J, Yang LH, Xu Y. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes. Clin Appl Thromb Hemost 2018; 24 (03) 462-470
    CrossrefPubMedSuche in Google Scholar